Sanofi replaces chief Paul Hudson with Merck executive
French drugmaker says incoming boss Belén Garijo will bring ‘increased rigour’
Related reading
Novo Nordisk’s new ‘king’ tightens his grip at obesity drug giant
Boardroom shake-up at European drugmaker grants Lars Rebien Sørensen wide-ranging powers
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
SocGen to axe 1,800 jobs in France as chief steps up cost cuts
Investors have started to reward turnaround effort under Slawomir Krupa
Merck nears deal for flu-prevention biotech Cidara
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda